Taysha Gene Therapies (TSHA) Competitors $2.03 0.00 (0.00%) (As of 09:40 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TSHA vs. EVO, ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, MESO, TVTX, and NTLAShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Taysha Gene Therapies vs. Evotec Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Travere Therapeutics Intellia Therapeutics Taysha Gene Therapies (NASDAQ:TSHA) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking. Do analysts rate TSHA or EVO? Taysha Gene Therapies presently has a consensus price target of $6.63, suggesting a potential upside of 226.35%. Evotec has a consensus price target of $5.93, suggesting a potential upside of 28.99%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, research analysts plainly believe Taysha Gene Therapies is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the MarketBeat Community favor TSHA or EVO? Taysha Gene Therapies received 98 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 77.04% of users gave Taysha Gene Therapies an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes10477.04% Underperform Votes3122.96% EvotecOutperform Votes654.55% Underperform Votes545.45% Is TSHA or EVO more profitable? Evotec has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -229.67%. Evotec's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-229.67% -106.36% -49.16% Evotec N/A N/A N/A Does the media favor TSHA or EVO? In the previous week, Evotec had 2 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 3 mentions for Evotec and 1 mentions for Taysha Gene Therapies. Evotec's average media sentiment score of 0.65 beat Taysha Gene Therapies' score of 0.00 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TSHA or EVO? Taysha Gene Therapies has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Which has higher earnings & valuation, TSHA or EVO? Evotec has higher revenue and earnings than Taysha Gene Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$9.92M41.96-$111.57M$0.633.22Evotec$777.05M2.10-$90.82MN/AN/A Do insiders and institutionals hold more shares of TSHA or EVO? 77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 2.7% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryTaysha Gene Therapies and Evotec tied by winning 8 of the 16 factors compared between the two stocks. Ad Wall Street StarHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$416.03M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio3.2247.02135.1917.53Price / Sales41.96420.131,224.59140.21Price / CashN/A182.1340.6537.95Price / Book5.083.924.884.92Net Income-$111.57M-$42.03M$118.97M$225.78M7 Day Performance-16.46%-3.37%15.53%-1.58%1 Month Performance-10.96%7.95%15.54%6.67%1 Year Performance31.82%21.00%34.63%22.48% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies3.4124 of 5 stars$2.03flat$6.63+226.4%+24.5%$416.03M$9.92M3.22180EVOEvotec1.4795 of 5 stars$4.68+4.2%$5.93+26.8%-56.6%$1.66B$777.05M0.005,061Short Interest ↓Gap DownARQTArcutis Biotherapeutics0.8059 of 5 stars$13.31+4.9%$15.50+16.5%+509.0%$1.56B$138.71M-7.58150Options VolumeNews CoverageNRIXNurix Therapeutics2.8431 of 5 stars$21.18+4.5%$30.35+43.3%+133.3%$1.50B$56.42M-6.97300RCUSArcus Biosciences2.7843 of 5 stars$16.25+1.1%$34.00+109.2%-11.3%$1.49B$117M-5.11500KNSAKiniksa Pharmaceuticals2.6661 of 5 stars$20.50+1.5%$36.60+78.5%+13.9%$1.48B$384.10M-147.36220Positive NewsIMCRImmunocore2.6216 of 5 stars$29.12+0.7%$65.64+125.4%-54.2%$1.46B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.797 of 5 stars$9.06+4.3%$16.71+84.5%+129.5%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.2998 of 5 stars$12.14+3.2%$11.50-5.3%+484.6%$1.39B$5.90M0.0080News CoverageGap UpTVTXTravere Therapeutics2.7223 of 5 stars$17.73+2.4%$22.62+27.6%+97.9%$1.38B$145.24M-3.81460Positive NewsNTLAIntellia Therapeutics4.1809 of 5 stars$13.50+4.7%$54.94+306.9%-57.3%$1.37B$36.28M-2.37600Short Interest ↑ Related Companies and Tools Related Companies EVO Alternatives ARQT Alternatives NRIX Alternatives RCUS Alternatives KNSA Alternatives IMCR Alternatives OCUL Alternatives MESO Alternatives TVTX Alternatives NTLA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TSHA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSHA Stock Alerts